{"name":"XEME Biopharma Inc.","slug":"xeme-biopharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxPUzFaNHMwNzJVOTBVblRHdE1SbWE1UW4zVHBFMzc4N0tENmdpODBxdVo0eVR4ZXFLb1VhdW14M1pqOVVaRTNlRDlrNTR2ZVZLMFYxQXJibUk3dVhVS0hPdDF3TmVHd25EOGlOUC1jemotWEZCNXQ2cldvZnlBc3dvcXNja3N0OU9nT2l6X3d1cDF5bFFPVFlSeG9zUm5xUDBqcEQyTjNnMWdRb1N3Z2hyMEREY2p4T3BkRmVpM05TVnAtU1FSdE5Ra2VXWmN6dUhEUlFuYnUxTGgxYndaTFdFVGVoVUpZblVkWWcxQXV3WkFnY3YzUkpSQ090UERZdkVmeEd5ZllHcVliaTE0WXJ4RTZvREVtbWkxSVVPQnhjMHJ0Mm5mQzR3QXROZXNvOEtYUzR6dHBOYmZlcnc?oc=5","date":"2026-02-19","type":"pipeline","source":"PR Newswire","summary":"Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight - PR Newswire","headline":"Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxNeWEyc0ZSQ29fczhyMHUxMG1ZUmk1YmM5bVdSOE1kOTFqQl9PRWZOV1FyMXJFdTZjSmNZdUwta3gySjJmN09xbkYydDhVQnRGU3E4RTJvb3Q1NnZSbzdLVmdoNTBhQUROT2hrbWRza3NFb2YzR1QtV3htZkFlbmNyWGM0anBEcXdzQ3NnZVpzdTVRX0FOenZJeDA1UVVWVTluai1yWS1QMWRWNExWTkxSMnBJZUdQUDE1Q1h1VGcyam1mdDlNbDJydTVTenUzZ1ZieWZkZGNKeVhJaXVway05RWxucnhjMkxMZFl4bkpleHhtaEJYQlhHXzhYcEt6LXpUVzVWLXdjUDFGbEl0UjBlenpORUp3Y3hqZFdUeFBzaW9XM2xnSV9IOG1VLXNQN3hZb1pPcEtfR0dZakZsRXFkeFBpdURTX3pDa1BXT1FpZjRmLXM?oc=5","date":"2025-09-17","type":"pipeline","source":"PR Newswire","summary":"Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies in Atopic Dermatitis, Asthma, CRSwNP, and Others | DelveInsight - PR Newswire","headline":"Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNSmVWVklxQTNpbHEzVGVrOHdzWlY1Ri1QRDJaUmFNLTBURDF1VTI2dFRxclJGMm1QRktiQ3dvalVhOFlIV0lhZGtTSGtTbGxacnBtUXozUjhKN1h2NHVib3cxR29Vbkk4cWwxWVZGSmtuazNWMTB2WUc5dE05TDRMc1UxaU1fU1NmbXE0QXFaX0xOV1Z6bkJxUnJfajNTV21yMTQxeFVBbERvOW90SDBQUG5DaG5wQVdYWjg1bnFzckV2UEJYWGRneWZQMDZ2ZEVZRmVuLVVzcVhQdVhGYU5ReDNjQTVacXpXaDNWM0EzckJodnNucVA0b195Y08wTnpLSWdwNDR0bE5OczFOSlBXbmFFOFVyU2RqT0V6RlNXQi0?oc=5","date":"2025-08-14","type":"regulatory","source":"PR Newswire","summary":"Interleukin-23 Inhibitors Market to Surge During the Forecast Period (2025-2034) Due to Demand for Targeted Autoimmune Therapies | DelveInsight - PR Newswire","headline":"Interleukin-23 Inhibitors Market to Surge During the Forecast Period (2025-2034) Due to Demand for Targeted Autoimmune T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxOSUtBeTVrV244MDBBX3NDdnVyaVJ5OS1IYWtkWEZNRmJRMnBiR2VreVctZmUyeWxvSHRJTUFLTUw2a09RYzJLR281NHl3a0tUSUJvZk42LTBLb1BmODFyMV9PM3B1T3RNTFVDaEJ3cHA5Z1JpcHRUMzdjSlJCbXhXWjFkWjBCMEFPdWlJQ0xiWkM4LUUwZ1R2aENSeU9ic2ZVSm54MzY5bVRMeTI0WFVjMXpZVEdNaklqZy1fX1hHc3hXd255V1lrQ2RfdmxVSlR2TDR3eGt4V3lFZHRoOTI0RmQtMWVxMEc1R21qNjgxdnhMZGpQWXBOcmVvVG1jR2pwLU5QSUNpbUdoWTNMajFfOG9XdXpoOFFJSkZkOHZpeGVoQWo5eXRYRVd1cnFvWDhjSlcwX2VTUFJBOWlSRlhwZ1ZNV3I?oc=5","date":"2025-07-21","type":"pipeline","source":"PR Newswire","summary":"Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight - PR Newswire","headline":"Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Ind","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxON3haaElHU09WM2UxVFAtWGQyRUtONkJKSURwc1E0bWVjVnRTVTRTVklWSFBiZURWLWgtQWhEcGFBNmZLM0FhTFFZeE5tWE90dnRVRzk2bVlVVFEzS3dtX3c5T3Y3allKd1E2UEhUbzJGdnk0SlR4Z2hsTkxHTy1XNTljamJJcnJ2WG5YVUd2RS1pWlE4aHp0WFR2TGU1WGcxa3Fabk0walIxdGZCXzg3amhpTkpJSm12ajR5akpkTVpuc1RaSUZKek1yZEc1WVFGWVkwSnZBX1Q2T0EtUmlaREM4eVl4T3RoRE1iZmpkTTk0VUM2NXRhdkdxc3ZNOEJMTVc3Zk5HcUp0bzdESU42OFN0cmQ1ZDFYX0JzdVZBV0gtZjY0cDQzUl9sQ01fSllFcjhhRA?oc=5","date":"2025-07-10","type":"trial","source":"GlobeNewswire","summary":"Interleukin-2 Inhibitors Clinical Trial Pipeline - GlobeNewswire","headline":"Interleukin-2 Inhibitors Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-03-27","type":"pipeline","source":"PR Newswire","summary":"The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Di","headline":"The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal ant","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}